AZN’s oncology pipeline is weighted toward “targeted” agents rather than I-O, so I’m not sure “exciting” is the most apt description. Imfinzi is distant fourth in the PD(L)-1 category. I would use the term "innovative" -- they are addressing a broad range of novel targets, most of which aren't me-toos. Immunooncology is crowded to say the least.